Drug Profile
Pelcitoclax - Ascentage Pharma
Alternative Names: APG 1252; APG 1252 12A; PalcitoclaxLatest Information Update: 25 Oct 2023
Price :
$50
*
At a glance
- Originator Ascentage Pharma
- Class Amines; Aniline compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Phosphonic acids; Piperazines; Piperidines; Pyrroles; Small molecules; Sulfonamides; Sulfones
- Mechanism of Action Bcl-X protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Myelofibrosis; Non-Hodgkin's lymphoma; Small cell lung cancer
- Phase I Neuroendocrine tumours
- Preclinical Gastric cancer; T-cell lymphoma
- No development reported Solid tumours
Most Recent Events
- 23 Oct 2023 Efficacy and adverse events data from a phase Ib trial in Non-small cell lung cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 28 Sep 2022 Pelcitoclax is still in phase I trials for Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion) (NCT04001777)
- 28 Sep 2022 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (IV) (Ascentage pipeline, September 2022)